Immatics N.V.(IMTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IMTX Immatics N.V.

盘后交易 09-26 18:36:51 EDT

11.73

-0.07

-0.59%

盘后11.73

+0.000.00%

16:00 EDT

最高11.97	最低11.67	成交量15.54万
今开11.85	昨收11.80	日振幅2.54%
总市值12.09亿	流通市值6.73亿	总股本1.03亿
成交额182.72万	换手率0.27%	流通股本5,736万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"IMTX","market":"US","secType":"STK","nameCN":"Immatics N.V.","latestPrice":11.73,"timestamp":1727380800000,"preClose":11.8,"halted":0,"volume":155436,"hourTrading":{"tag":"盘后","latestPrice":11.73,"preClose":11.73,"latestTime":"16:00 EDT","volume":3270,"amount":38357.1,"timestamp":1727380806305},"delay":0,"floatShares":57362187,"shares":103105906,"eps":-0.853772,"marketStatus":"盘后交易","marketStatusCode":4,"change":-0.07,"latestTime":"09-26 18:36:51 EDT","open":11.85,"high":11.97,"low":11.67,"amount":1827167.122524,"amplitude":0.025424,"askPrice":13.11,"askSize":100,"bidPrice":10.32,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.853772,"exchange":"NASDAQ","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1727395200000},"adr":0,"adjPreClose":11.8,"preHourTrading":{"tag":"盘前","latestPrice":11.8,"preClose":11.8,"latestTime":"08:00 EDT","volume":6,"amount":70.80000000000001,"timestamp":1727352000440},"postHourTrading":{"tag":"盘后","latestPrice":11.73,"preClose":11.73,"latestTime":"16:00 EDT","volume":3270,"amount":38357.1,"timestamp":1727380806305},"volumeRatio":0.542298,"impliedVol":0.5201,"impliedVolPercentile":0.254},"requestUrl":"/m/hq/s/IMTX","defaultTab":"news","newsList":[{"id":"2459152417","title":"Immatics N.V.2024财年第二财季实现净利润-19.40百万美元，同比增加27.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459152417","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459152417?lang=zh_cn&edition=full","pubTime":"2024-08-14 07:08","pubTimestamp":1723590511,"startTime":"0","endTime":"0","summary":"8月14日，Immatics N.V.公布财报，公告显示公司2024财年第二财季净利润为-19.40百万美元，同比增加27.56%；其中营业收入为20.19百万美元，同比减少17.02%，每股基本收益为-0.18美元。从资产负债表来看，Immatics N.V.总负债2.56亿美元，其中短期债务23.34百万美元，资产负债比为2.63，流动比率为3.75。机构评级：截至2024年8月14日，当前有5家机构对Immatics N.V.目标价做出预测，其中目标均价为18.10美元，其中最低目标价为14.16美元，最高目标价为20.22美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408140708379f289132&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408140708379f289132&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMTX"],"gpt_icon":0},{"id":"2453064734","title":"Immatics N.V.盘中异动 下午盘急速上涨5.10%报12.98美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2453064734","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453064734?lang=zh_cn&edition=full","pubTime":"2024-07-24 03:27","pubTimestamp":1721762863,"startTime":"0","endTime":"0","summary":"北京时间2024年07月24日03时27分，Immatics N.V.股票出现异动，股价快速上涨5.10%。截至发稿，该股报12.98美元/股，成交量52.5168万股，换手率0.51%，振幅6.68%。Immatics N.V.股票所在的生物技术行业中，整体跌幅为0.09%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，致力于研究和开发用于治疗癌症患者的 T 细胞重定向免疫疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240724032744aefb0a09&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240724032744aefb0a09&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMTX","BK4139"],"gpt_icon":0},{"id":"2450545534","title":"Immatics N.V.盘中异动 快速上涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450545534","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450545534?lang=zh_cn&edition=full","pubTime":"2024-07-12 22:29","pubTimestamp":1720794549,"startTime":"0","endTime":"0","summary":"北京时间2024年07月12日22时29分，Immatics N.V.股票出现波动，股价快速上涨5.07%。截至发稿，该股报12.86美元/股，成交量7.3815万股，换手率0.07%，振幅5.47%。Immatics N.V.股票所在的生物技术行业中，整体涨幅为1.45%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，致力于研究和开发用于治疗癌症患者的 T 细胞重定向免疫疗法。该公司通过与第三方制药和生物技术公司的战略合作协议获得收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712222909aef97c9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712222909aef97c9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMTX"],"gpt_icon":0},{"id":"2442435153","title":"Immatics N.V.盘中异动 股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2442435153","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2442435153?lang=zh_cn&edition=full","pubTime":"2024-06-12 02:42","pubTimestamp":1718131360,"startTime":"0","endTime":"0","summary":"北京时间2024年06月12日02时42分，Immatics N.V.股票出现波动，股价急速上涨5.05%。截至发稿，该股报13.53美元/股，成交量33.055万股，换手率0.32%，振幅6.99%。Immatics N.V.股票所在的生物技术行业中，整体跌幅为0.28%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，致力于研究和开发用于治疗癌症患者的 T 细胞重定向免疫疗法。该公司通过与第三方制药和生物技术公司的战略合作协议获得收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240612024241968136e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240612024241968136e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMTX","BK4139"],"gpt_icon":0},{"id":"2441820802","title":"Immatics N.V.盘中异动 股价大涨5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2441820802","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441820802?lang=zh_cn&edition=full","pubTime":"2024-06-05 23:45","pubTimestamp":1717602350,"startTime":"0","endTime":"0","summary":"北京时间2024年06月05日23时45分，Immatics N.V.股票出现异动，股价快速上涨5.39%。截至发稿，该股报13.09美元/股，成交量18.8343万股，换手率0.18%，振幅5.55%。Immatics N.V.股票所在的生物技术行业中，整体涨幅为1.28%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，致力于研究和开发用于治疗癌症患者的 T 细胞重定向免疫疗法。该公司通过与第三方制药和生物技术公司的战略合作协议获得收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240605234550aef39270&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240605234550aef39270&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMTX","BK4139"],"gpt_icon":0},{"id":"2437302860","title":"Immatics N.V.盘中异动 股价大涨5.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2437302860","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2437302860?lang=zh_cn&edition=full","pubTime":"2024-05-24 21:49","pubTimestamp":1716558554,"startTime":"0","endTime":"0","summary":"北京时间2024年05月24日21时49分，Immatics N.V.股票出现异动，股价快速拉升5.91%。截至发稿，该股报10.40美元/股，成交量18.46万股，换手率0.18%，振幅4.89%。Immatics N.V.股票所在的生物技术行业中，整体涨幅为0.25%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，致力于研究和开发用于治疗癌症患者的 T 细胞重定向免疫疗法。该公司通过与第三方制药和生物技术公司的战略合作协议获得收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240524214915af8a2c40&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240524214915af8a2c40&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMTX","BK4139"],"gpt_icon":0},{"id":"2435676875","title":"瑞穗银行：维持Immatics(IMTX.US)评级，由买入调整至买入评级, 目标价由14.00美元调整至16.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2435676875","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2435676875?lang=zh_cn&edition=full","pubTime":"2024-05-16 19:16","pubTimestamp":1715858213,"startTime":"0","endTime":"0","summary":"瑞穗银行：维持Immatics(IMTX.US)评级，由买入调整至买入评级, 目标价由14.00美元调整至16.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051619165887704cf2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051619165887704cf2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMTX"],"gpt_icon":0},{"id":"2435759886","title":"瑞穗银行：维持Immatics(IMTX.US)评级，由买入调整至买入评级, 目标价由14.00美元调整至16.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2435759886","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2435759886?lang=zh_cn&edition=full","pubTime":"2024-05-16 19:08","pubTimestamp":1715857736,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","IMTX","161121"],"gpt_icon":0},{"id":"2435968809","title":"近90%患者肿瘤缩小！Immatics(IMTX.US)创新细胞疗法2/3期试验即将启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2435968809","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2435968809?lang=zh_cn&edition=full","pubTime":"2024-05-15 15:28","pubTimestamp":1715758122,"startTime":"0","endTime":"0","summary":"IMA203是由Immatics专有ACTengine平台所开发的TCR-T细胞，靶向由HLA-A*02呈递的黑素瘤抗原PRAME。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20240515/20240515152915_29906.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240515/20240515152915_29906.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1121493.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["IMTX","BK4139"],"gpt_icon":0},{"id":"2435688040","title":"【近90%患者肿瘤缩小！Immatics(IMTX.US)创新细胞疗法2/3期试验即将启动】智通财经APP获悉，Immatics公司(IMTX.","url":"https://stock-news.laohu8.com/highlight/detail?id=2435688040","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2435688040?lang=zh_cn&edition=full","pubTime":"2024-05-15 15:28","pubTimestamp":1715758122,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03347","BK1576","BK4139","BK1141","IMTX","BK1583"],"gpt_icon":0},{"id":"2435554889","title":"Immatics(IMTX.US)：2024年Q1财报实现营收3287.4万美元，前值为1051.3万美元，预期值为2187万美元；","url":"https://stock-news.laohu8.com/highlight/detail?id=2435554889","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2435554889?lang=zh_cn&edition=full","pubTime":"2024-05-14 23:32","pubTimestamp":1715700737,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IMTX","BK4139"],"gpt_icon":0},{"id":"2435519032","title":"Immatics N.V.盘中异动 早盘快速拉升7.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2435519032","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2435519032?lang=zh_cn&edition=full","pubTime":"2024-05-14 21:32","pubTimestamp":1715693574,"startTime":"0","endTime":"0","summary":"北京时间2024年05月14日21时32分，Immatics N.V.股票出现异动，股价快速拉升7.27%。截至发稿，该股报11.80美元/股，成交量2.1404万股，换手率0.02%，振幅2.55%。Immatics N.V.股票所在的生物技术行业中，整体涨幅为0.14%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，致力于研究和开发用于治疗癌症患者的 T 细胞重定向免疫疗法。该公司通过与第三方制药和生物技术公司的战略合作协议获得收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405142132548b07d7bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405142132548b07d7bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMTX","BK4139"],"gpt_icon":0},{"id":"2432801126","title":"Immatics N.V.盘中异动 下午盘大幅拉升5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432801126","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2432801126?lang=zh_cn&edition=full","pubTime":"2024-05-02 02:27","pubTimestamp":1714588064,"startTime":"0","endTime":"0","summary":"北京时间2024年05月02日02时27分，Immatics N.V.股票出现异动，股价急速上涨5.04%。截至发稿，该股报10.43美元/股，成交量24.0438万股，换手率0.23%，振幅4.73%。Immatics N.V.股票所在的生物技术行业中，整体涨幅为1.45%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，致力于研究和开发用于治疗癌症患者的 T 细胞重定向免疫疗法。该公司通过与第三方制药和生物技术公司的战略合作协议获得收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240502022744861ea914&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240502022744861ea914&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMTX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immatics.com","stockEarnings":[{"period":"1week","weight":-0.032},{"period":"1month","weight":0.027},{"period":"3month","weight":0.0008},{"period":"6month","weight":0.1227},{"period":"1year","weight":0.0573},{"period":"ytd","weight":0.1206}],"compareEarnings":[{"period":"1week","weight":0.0154},{"period":"1month","weight":0.0165},{"period":"3month","weight":0.0433},{"period":"6month","weight":0.0898},{"period":"1year","weight":0.3385},{"period":"ytd","weight":0.1993}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Immatics N.V.是一家荷兰私人有限责任公司，于2020年3月10日成立。该公司是一家专注于开发基于T细胞受体的免疫疗法的生物制药公司。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.063537},{"month":2,"riseRate":0.75,"avgChangeRate":-0.011615},{"month":3,"riseRate":0.25,"avgChangeRate":-0.076889},{"month":4,"riseRate":0.5,"avgChangeRate":0.010902},{"month":5,"riseRate":0.5,"avgChangeRate":0.086457},{"month":6,"riseRate":1,"avgChangeRate":0.113651},{"month":7,"riseRate":1,"avgChangeRate":0.09814},{"month":8,"riseRate":0.4,"avgChangeRate":-0.003927},{"month":9,"riseRate":0.4,"avgChangeRate":-0.012838},{"month":10,"riseRate":0.5,"avgChangeRate":-0.032187},{"month":11,"riseRate":0.25,"avgChangeRate":-0.034864},{"month":12,"riseRate":0.75,"avgChangeRate":0.065405}],"exchange":"NASDAQ","name":"Immatics N.V.","nameEN":"Immatics N.V."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.0","shortVersion":"4.28.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immatics N.V.(IMTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Immatics N.V.(IMTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Immatics N.V.,IMTX,Immatics N.V.股票,Immatics N.V.股票老虎,Immatics N.V.股票老虎国际,Immatics N.V.行情,Immatics N.V.股票行情,Immatics N.V.股价,Immatics N.V.股市,Immatics N.V.股票价格,Immatics N.V.股票交易,Immatics N.V.股票购买,Immatics N.V.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immatics N.V.(IMTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Immatics N.V.(IMTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}